These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus. Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276 [TBL] [Abstract][Full Text] [Related]
8. Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Nübling CM; Chudy M; Löwer J Biologicals; 1999 Dec; 27(4):291-4. PubMed ID: 10686055 [TBL] [Abstract][Full Text] [Related]
9. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations. Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035 [TBL] [Abstract][Full Text] [Related]
10. Assessment of needs for plasma for fractionation in Europe. Burckhardt JJ Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061 [TBL] [Abstract][Full Text] [Related]
11. NAT: perspectives for cellular components. Barbara JA Biologicals; 1999 Dec; 27(4):333-6. PubMed ID: 10686060 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. Baylis SA; Shah N; Minor PD J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727 [TBL] [Abstract][Full Text] [Related]
13. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Busch MP; Glynn SA; Wright DJ; Hirschkorn D; Laycock ME; McAuley J; Tu Y; Giachetti C; Gallarda J; Heitman J; Kleinman SH; Transfusion; 2005 Dec; 45(12):1853-63. PubMed ID: 16371038 [TBL] [Abstract][Full Text] [Related]
14. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR; Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. McCormick MK; Dockter J; Linnen JM; Kolk D; Wu Y; Giachetti C J Clin Virol; 2006 Jul; 36(3):166-76. PubMed ID: 16427802 [TBL] [Abstract][Full Text] [Related]
16. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors. Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176 [TBL] [Abstract][Full Text] [Related]
18. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Koppelman MH; Assal A; Chudy M; Torres P; de Villaescusa RG; Reesink HW; Lelie PN; Cuypers HT Transfusion; 2005 Aug; 45(8):1258-66. PubMed ID: 16078910 [TBL] [Abstract][Full Text] [Related]
19. Assessment of validation studies from a fractionator's point of view. Zerlauth G Biologicals; 1999 Dec; 27(4):295-301. PubMed ID: 10686056 [TBL] [Abstract][Full Text] [Related]
20. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. Dettori S; Candido A; Kondili LA; Chionne P; Taffon S; Genovese D; Iudicone P; Miceli M; Rapicetta M J Infect; 2009 Aug; 59(2):128-33. PubMed ID: 19586663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]